Cyprus-based medical technology startup MammoCheck has won first place at the 16th NBG Business Seeds Innovation and Technology Competition, emerging as the overall winner from 344 entries submitted from Greece, Cyprus and other countries.
The annual competition, organised by the National Bank of Greece, announced the results during an awards ceremony in Athens. MammoCheck received the competition’s top distinction along with a €20,000 cash prize.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Founded in 2024 as a spin-out from Frederick University, MammoCheck is developing an artificial intelligence-powered Software as a Medical Device (SaMD) platform designed to support breast cancer screening. The solution combines a smartphone application with low-cost thermal cameras to provide an adjunctive screening tool powered by AI.
The company says its technology aims to address a significant gap in breast cancer screening, with hundreds of millions of women worldwide lacking regular access to mammography, including many women under the age of 45 who are not covered by most national screening programmes.
“We are honoured to receive first place among 344 entries from Greece, Cyprus and abroad. This recognition reflects the dedication of our team, our clinical partners and the women who inspire our work every day,”
said Alexandra Dimitriadou, co-founder and CEO of MammoCheck.
MammoCheck is currently conducting a clinical trial across multiple hospital sites as it advances toward FDA 510(k) clearance in the United States and CE marking under the European Union’s Medical Device Regulation (MDR).
The latest award marks another milestone for Cyprus’ growing health technology ecosystem, highlighting the increasing international visibility of locally developed medical innovations.
